SCHEMBL4445137

SCHEMBL4445137

CC(=O)Nc1cccc2c(S(=O)(=O)N3Cc4ccccc4C3)cccc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EDNRA P25101 1/20 0.48
KMT2A Q03164 2/20 0.45
CCR8 P51685 1/20 0.45
SLC40A1 Q9NP59 1/20 0.44
RXFP1 Q9HBX9 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
ESR1 P03372 1/20 0.43
ESR2 Q92731 1/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
MAOA P21397 1/20 0.42
ALDH1A1 P00352 2/20 0.41
AKR1C3 P42330 1/20 0.41
AKR1C1 Q04828 1/20 0.41
MEN1 O00255 1/20 0.41
KDM4E B2RXH2 1/20 0.41
TAAR1 Q96RJ0 1/20 0.41
PKM P14618 1/20 0.41
TP53 P04637 1/20 0.41
CASP6 P55212 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4455025 0.92 KMT2A (0.52) KMT2ASMN1; SMN2ESR1ESR2ALDH1A1
SCHEMBL6073527 0.76 CASP6 (0.60) EDNRAKMT2ASLC40A1RXFP1MAOA
SCHEMBL15461567 0.76 EDNRA (0.54) EDNRAKMT2ASLC40A1RXFP1MAOA
SCHEMBL3147733 0.75 HTR6 (0.70)
SCHEMBL3529089 0.75 EDNRA (0.53) EDNRAKMT2ASLC40A1RXFP1SMN1; SMN2
SCHEMBL4446896 0.75 CCR8 (0.64) EDNRAKMT2ACCR8SLC40A1MEN1
SCHEMBL4449287 0.74 TTR (0.51) KMT2ASMN1; SMN2ESR1ESR2MEN1
Hydrochloric Acid SCHEMBL8054311 0.74 CDK2 (0.53) EDNRAKMT2ARXFP1ALDH1A1MEN1
SCHEMBL21878720 0.74 EDNRA (0.52) EDNRAKMT2ASLC40A1RXFP1SMN1; SMN2
SCHEMBL6073751 0.74 EDNRA (0.58) EDNRAKMT2ACCR8SLC40A1RXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7547716-B2 Sulfonamide derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2009-06-16 US disclosed
EP-1402890-B1 SULFONAMIDE DERIVATIVES INST MED MOLECULAR DESIGN INC (JP) 2008-01-09 EP disclosed
US-20040234622-A1 Sulfonamide derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2004-11-25 US disclosed
EP-1402890-A1 SULFONAMIDE DERIVATIVES Institute of Medicinal Molecular Design, Inc. (JP) 2004-03-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040234622-A1 Sulfonamide derivatives PCNA, TOP2A, DDB1 EDNRA 1812/4885KMT2A 460/4885CCR8 2931/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.